$8.43
6.04% yesterday
Nasdaq, Sep 03, 10:00 pm CET
ISIN
US50127T1097
Symbol
KURA

Kura Oncology, Inc. Target price 2025 - Analyst rating & recommendation

Kura Oncology, Inc. Classifications & Recommendation:

Buy
86%
Hold
14%

Kura Oncology, Inc. Price Target

Target Price $26.01
Price $8.43
Potential
Number of Estimates 14
14 Analysts have issued a price target Kura Oncology, Inc. 2026 . The average Kura Oncology, Inc. target price is $26.01. This is higher than the current stock price. The highest price target is , the lowest is .
A rating was issued by 21 analysts: 18 Analysts recommend Kura Oncology, Inc. to buy, 3 to hold and 0 to sell.
Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis.
Analyst Estimates: Analysts believe that the Kura Oncology, Inc. stock has an average upside potential 2026 of . Most analysts recommend the Kura Oncology, Inc. stock at Purchase.

Sales and Margin forecast 2025, 2026 to 2032

Create a premium account to unlock analyst estimates. Learn more

Quarter Annually
Dec '24 2025
Estimates
Revenue Million $ 53.88 86.35
60.26%
EBITDA Margin -357.00% -276.51%
22.55%
Net Margin -322.90% -259.15%
19.74%

17 Analysts have issued a sales forecast Kura Oncology, Inc. 2025 . The average Kura Oncology, Inc. sales estimate is

$86.3m
Unlock
. This is
3.68% higher
Unlock
than the revenue of the last 12 months(TTM). The highest sales forecast is
$171m 105.51%
Unlock
, the lowest is
$29.1m 65.00%
Unlock
.

This results in the following potential growth metrics:

Revenue Estimates

2024 $53.9m
2025
$86.3m 60.26%
Unlock
2026
$220m 155.10%
Unlock
2027
$216m 1.97%
Unlock
2028
$582m 169.55%
Unlock
2029
$872m 49.81%
Unlock
2030
$1.4b 63.64%
Unlock
2031
$818m 42.65%
Unlock
2032
$997m 21.87%
Unlock

5 Analysts have issued an Kura Oncology, Inc. EBITDA forecast 2025. The average Kura Oncology, Inc. EBITDA estimate is

$-239m
Unlock
. This is
9.11% lower
Unlock
than the EBITDA of the last 12 months(TTM). The highest EBITDA forecast is
$-185m 15.32%
Unlock
, the lowest is
$-292m 33.40%
Unlock
.

This results in the following potential growth metrics and future EBITDA Margins:

EBITDA Estimates

2024 $-192m 16.60%
2025
$-239m 24.13%
Unlock
2026
$-274m 14.80%
Unlock
2027
$-356m 29.79%
Unlock
2028
$-306m 13.93%
Unlock
2029
$-203m 33.54%
Unlock

EBITDA Margin

2024 -357.00%
2025
-276.51% 22.55%
Unlock
2026
-124.44% 55.00%
Unlock
2027
-164.75% 32.39%
Unlock
2028
-52.61% 68.07%
Unlock
2029
-23.34% 55.64%
Unlock

16 Kura Oncology, Inc. Analysts have issued a net profit forecast 2025. The average Kura Oncology, Inc. net profit estimate is

$-224m
Unlock
. This is
13.49% lower
Unlock
than the net profit for the last 12 months(TTM). The highest net profit forecast is
$-143m 27.43%
Unlock
, the lowest is
$-288m 46.25%
Unlock
.

This results in the following potential growth metrics and future Net Margins:

Net Profit Estimates

2024 $-174m 13.99%
2025
$-224m 28.62%
Unlock
2026
$-228m 2.03%
Unlock
2027
$-225m 1.28%
Unlock
2028
$-24.6m 89.08%
Unlock
2029
$168m 784.27%
Unlock
2030
$575m 241.34%
Unlock
2031
$105m 81.78%
Unlock
2032
$247m 135.80%
Unlock

Net Margin

2024 -322.90%
2025
-259.15% 19.74%
Unlock
2026
-103.66% 60.00%
Unlock
2027
-104.37% 0.68%
Unlock
2028
-4.23% 95.95%
Unlock
2029
19.31% 556.50%
Unlock
2030
40.28% 108.60%
Unlock
2031
12.80% 68.22%
Unlock
2032
24.77% 93.52%
Unlock

Earnings per share, P/E ratio and EV/sales Estimates 2025, 2026 to 2032

Create a premium account to unlock analyst estimates. Learn more

Quarter Annually
Dec '24 2025
Estimates
Earnings Per Share $ -2.02 -2.58
2.88% 27.72%
P/E negative
EV/Sales 0.80

16 Analysts have issued a Kura Oncology, Inc. forecast for earnings per share. The average Kura Oncology, Inc. EPS is

$-2.58
Unlock
. This is
14.16% lower
Unlock
than earnings per share in the financial year 2024. The highest EPS forecast is
$-1.65 26.99%
Unlock
, the lowest is
$-3.32 46.90%
Unlock
.

This results in the following potential growth metrics and future valuations:

Earnings Per Share

2024 $-2.02 2.88%
2025
$-2.58 27.72%
Unlock
2026
$-2.63 1.94%
Unlock
2027
$-2.60 1.14%
Unlock
2028
$-0.28 89.23%
Unlock
2029
$1.94 792.86%
Unlock
2030
$6.62 241.24%
Unlock
2031
$1.21 81.72%
Unlock
2032
$2.85 135.54%
Unlock

P/E ratio

Current -3.52 65.09%
2025
-3.08 12.44%
Unlock
2026
-3.02 1.95%
Unlock
2027
-3.06 1.32%
Unlock
2028
-28.04 816.34%
Unlock
2029
4.10 114.62%
Unlock
2030
1.20 70.73%
Unlock
2031
6.59 449.17%
Unlock
2032
2.79 57.66%
Unlock

Based on analysts' sales estimates for 2025, the Kura Oncology, Inc. stock is valued at an EV/Sales of

and an P/S ratio of .

This results in the following potential growth metrics and future valuations:

EV/Sales

Current 0.83
2025
0.80 3.82%
Unlock
2026
0.31 60.80%
Unlock
2027
0.32 2.01%
Unlock
2028
0.12 62.91%
Unlock
2029
0.08 33.28%
Unlock
2030
0.05 38.86%
Unlock
2031
0.08 74.33%
Unlock
2032
0.07 17.93%
Unlock

P/S ratio

Current
2025
7.99 3.55%
Unlock
2026
3.13 60.80%
Unlock
2027
3.20 2.00%
Unlock
2028
1.19 62.90%
Unlock
2029
0.79 33.25%
Unlock
2030
0.48 38.89%
Unlock
2031
0.84 74.36%
Unlock
2032
0.69 17.94%
Unlock

Current Kura Oncology, Inc. Upgrades & Downgrades

Create a Premium account to unlock Upgrades/Downgrades. Learn more
Analyst Rating Action Date
JMP Securities
Locked
Locked
Locked Aug 11 2025
Cantor Fitzgerald
Locked
Locked
Locked Jun 26 2025
Wedbush
Locked
Locked
Locked Jun 20 2025
JMP Securities
Locked
Locked
Locked Jun 04 2025
Mizuho
Locked
Locked
Locked May 19 2025
Barclays
Locked
Locked
Locked May 02 2025
JMP Securities
Locked
Locked
Locked Apr 29 2025
Analyst Rating Date
Locked
JMP Securities:
Locked
Locked
Aug 11 2025
Locked
Cantor Fitzgerald:
Locked
Locked
Jun 26 2025
Locked
Wedbush:
Locked
Locked
Jun 20 2025
Locked
JMP Securities:
Locked
Locked
Jun 04 2025
Locked
Mizuho:
Locked
Locked
May 19 2025
Locked
Barclays:
Locked
Locked
May 02 2025
Locked
JMP Securities:
Locked
Locked
Apr 29 2025

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today